MoonLake Immunotherapeutics
NASDAQMoonLake Immunotherapeutics heads into the week with a sharp contradiction at its core: options traders are the most bullish they have been all year, while the founders and CFO have been selling stock steadily into the same rally that drove shares up 12% on the week. The options signal is striking. The put/call ratio collapsed to 0.11 — nearly three standard deviations below its…
MLTX cost-to-borrow surges 219% in one week to 0.45%, reversing recent decline as shares become scarcer relative to short interest.
Snapshot as of 24 Jun 2026
MoonLake Immunotherapeutics heads into the week with a sharp contradiction at its core: options traders are the most bullish they have been all year, while the founders and CFO have been selling stock steadily into the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MLTX — free to start on ORTEX.
Sign up for free →Open MLTX on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live MLTX data →